Portfolio concentration
As of February 28, 2025 · N-PORT
Holdings
76
Top-10 weight
26.84%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
60
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
221.1
Holdings
As of February 28, 2025 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | RECURSION PHARMACEUTICALS INC | — | 47,707 | $358.28K | 4.01% |
| 2 | PRECIGEN INC | — | 157,416 | $272.33K | 3.05% |
| 3 | COMPASS THERAPEUTICS INC | — | 92,038 | $266.91K | 2.99% |
| 4 | GENELUX CORP | — | 61,963 | $259.01K | 2.90% |
| 5 | SPRINGWORKS THERAPEUTICS INC | — | 4,426 | $255.65K | 2.86% |
| 6 | EXELIXIS INC | — | 5,730 | $221.69K | 2.48% |
| 7 | GINKGO BIOWORKS HOLDINGS INC | — | 25,263 | $208.17K | 2.33% |
| 8 | REPLIMUNE GROUP INC | — | 15,047 | $190.80K | 2.14% |
| 9 | BRISTOL-MYERS SQUIBB CO | — | 3,149 | $187.74K | 2.10% |
| 10 | SCHRODINGER INC | — | 7,925 | $176.81K | 1.98% |
| 11 | BLUEPRINT MEDICINES CORP | — | 1,824 | $176.14K | 1.97% |
| 12 | ZYMEWORKS INC | — | 12,581 | $168.59K | 1.89% |
| 13 | VOR BIOPHARMA INC | — | 155,827 | $168.29K | 1.88% |
| 14 | HUTCHMED CHINA LTD ADR | HCM | 9,522 | $156.73K | 1.76% |
| 15 | Innate Pharma SA | IPHA | 72,695 | $154.11K | 1.73% |
| 16 | MONTE ROSA THERAPEUTICS INC | — | 28,005 | $154.03K | 1.73% |
| 17 | IMMUNITYBIO INC | — | 45,097 | $148.37K | 1.66% |
| 18 | MERUS NV | MRUS | 3,136 | $147.67K | 1.65% |
| 19 | ENLIVEN THERAPEUTICS INC | — | 7,033 | $146.50K | 1.64% |
| 20 | REVOLUTION MEDICINES INC | — | 3,534 | $143.98K | 1.61% |
| 21 | BIONTECH SE ADR | — | 1,275 | $143.97K | 1.61% |
| 22 | Immunocore Holdings plc ADS | IMCR US | 4,770 | $140.09K | 1.57% |
| 23 | SYNDAX PHARMACEUTICALS INC | — | 8,648 | $135.25K | 1.51% |
| 24 | GENMAB A/S -SP ADR DEPOSITARY RECEIPT | GMAB | 5,921 | $134.29K | 1.50% |
| 25 | ARCELLX INC | — | 2,045 | $132.56K | 1.48% |
| 26 | MERCK & CO | — | 1,335 | $123.15K | 1.38% |
| 27 | INHIBRX BIOSCIENCES INC | — | 9,030 | $119.65K | 1.34% |
| 28 | AURA BIOSCIENCES INC | — | 15,787 | $118.24K | 1.32% |
| 29 | XENCOR INC | — | 7,442 | $114.31K | 1.28% |
| 30 | MACROGENICS INC | — | 45,885 | $112.88K | 1.26% |
| 31 | ALLOGENE THERAPEUTICS INC | — | 57,024 | $111.20K | 1.25% |
| 32 | ARVINAS INC | — | 6,259 | $110.78K | 1.24% |
| 33 | SUMMIT THERAPEUTICS INC | — | 5,340 | $110.48K | 1.24% |
| 34 | KARYOPHARM THERAPEUTICS INC | — | 13,708 | $108.98K | 1.22% |
| 35 | LEGEND BIOTECH CORP SPON ADR | — | 3,069 | $107.45K | 1.20% |
| 36 | NUVALENT INC-A | — | 1,404 | $105.27K | 1.18% |
| 37 | DAY ONE BIOPHARMACEUTICALS INC | — | 11,547 | $104.62K | 1.17% |
| 38 | JANUX THERAPEUTICS INC | — | 3,155 | $103.77K | 1.16% |
| 39 | KYMERA THERAPEUTICS INC | — | 3,247 | $101.79K | 1.14% |
| 40 | ACRIVON THERAPEUTICS INC | — | 19,124 | $101.55K | 1.14% |
| 41 | ARCUS BIOSCIENCES INC | — | 9,313 | $101.42K | 1.14% |
| 42 | NUVATION BIO INC | — | 51,266 | $100.99K | 1.13% |
| 43 | REGENERON PHARMACEUTICALS INC | — | 137 | $95.73K | 1.07% |
| 44 | NURIX THERAPEUTICS INC | — | 6,187 | $95.59K | 1.07% |
| 45 | RAPT THERAPEUTICS INC | — | 83,716 | $95.44K | 1.07% |
| 46 | ITEOS THERAPEUTICS INC | — | 13,008 | $94.44K | 1.06% |
| 47 | ADICET BIO INC | — | 104,924 | $94.31K | 1.06% |
| 48 | TYRA BIOSCIENCES INC | — | 7,811 | $91.47K | 1.02% |
| 49 | CARIBOU BIOSCIENCES INC | — | 77,530 | $90.71K | 1.02% |
| 50 | IMMUNEERING CORP | — | 54,838 | $90.48K | 1.01% |
1 / 2
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.